Table 2.
Pharmacological therapy at discharge/end visit according to baseline LDL-C levels.
| Total (n. 3074) | LDL-C < 70 mg/dl (n. 1186) | LDL-C 70–99 mg/dl (n. 1150) | LDL-C ≥ 100 mg/dl (n. 738) | p | |
|---|---|---|---|---|---|
| Oral anticoagulants, n (%) | 288 (9.4) | 110 (9.3) | 98 (8.5) | 80 (10.8) | 0.24 |
| ASA, n (%) | 2785 (90.6) | 1086 (91.6) | 1050 (91.3) | 649 (87.9) | 0.02 |
| Thienopyridine, §n (%) | 1597 (52.0) | 614 (51.8) | 556 (48.4) | 427 (57.9) | 0.0003 |
| ASA/thienopyridine, n (%) | 2946 (95.8) | 1140 (96.1) | 1103 (95.9) | 703 (95.3) | 0.64 |
| DAPT (ASA + thienopyridine), n (%) | 1436 (46.7) | 560 (47.2) | 503 (43.7) | 373 (50.5) | 0.01 |
| ACE-inhibitors, n (%) | 1735 (56.4) | 694 (58.5) | 635 (55.2) | 406 (55.0) | 0.18 |
| ARBs, n (%) | 690 (22.5) | 269 (22.7) | 274 (23.8) | 147 (19.9) | 0.14 |
| ACE/ARBs | 2405 (78.2) | 958 (80.8) | 902 (78.4) | 545 (73.9) | 0.002 |
| Beta-blockers, n (%) | 2457 (79.9) | 976 (82.3) | 914 (79.5) | 567 (76.8) | 0.01 |
| Mineralcorticoid antagonists (MRAs), n (%) | 334 (10.9) | 138 (11.6) | 123 (10.7) | 73 (9.9) | 0.48 |
| Statins, n (%) | 2928 (95.3) | 1152 (97.1) | 1106 (96.2) | 670 (90.8) | <0.0001 |
| Low-dose statins | 286 (9.3) | 105 (8.9) | 130 (11.3) | 51 (6.9) | 0.005 |
| High-intensity statins | 1888 (61.4) | 753 (63.5) | 690 (60.0) | 445 (60.3) | 0.17 |
| Dose of statins (mg), mean SD) | |||||
| Atorvastatin | 40 [40-40] | 40 [20–40] | 40 [40-40] | 40 [40–80] | 0.0009 |
| Fluvastatin | 80 [80-80] | — | 45 [10–80] | 80 [80-80] | 0.41 |
| Lovastatin | 20 [20–40] | 30 [20–40] | 20 [20–40] | 40 [20–40] | 0.66 |
| Pravastatin | 40 [40-40] | 40 [40-40] | 40 [40-40] | 40 [40-40] | 0.73 |
| Rosuvastatin | 15 [10–20] | 10 [10–20] | 20 [10–20] | 20 [10–20] | 0.09 |
| Simvastatin | 20 [20–40] | 20 [20–40] | 20 [20–40] | 40 [20–40] | 0.02 |
ASA, aspirin; DAPT, dual antiplatelet therapy, ACE angiotensin converting enzyme; ARB, angiotensin receptor blockers.
§Clopidogrei/prasugrel/ticagrelor/ticlopidina.